Butt Implants: Device Choices, Risks and Evidence

Butt implants add volume through a surgically placed gluteal device. They are different from transferring your own fat, removing loose buttock skin or injecting a filler. An implant proposal needs to specify the exact device, intended contour, tissue coverage, incision and recovery plan. It should also explain possible infection, wound problems, displacement and future removal or revision rather than presenting the device as a permanent, maintenance-free answer.

ASPS describes buttock augmentation with implants, fat grafting or a combination, while distinguishing augmentation from a skin-lift task. Its overview explains these different goals. The decision is whether a device-based plan fits your anatomy and priorities, with acceptable limitations. A lack of donor fat can be part of that discussion, but it does not establish implant candidacy by itself.

Identify the contour task before choosing a material

Adding volume and removing excess skin are different endpoints. Describe whether the concern is projection from the side, upper fullness, asymmetry, overall shape or loose skin. An operation that changes one region should not be assumed to address every part of the buttock and hip. Ask which area the proposed device is intended to change and what is expected to remain unchanged.

Use ordinary activities and clothing fit to explain your priorities, as well as photographs. A fitted garment or a posed image may emphasize a silhouette without explaining what tissue change is needed. Ask the clinician to translate a desired appearance into an achievable, region-specific goal rather than choosing an implant volume from a photo online.

Discuss each side separately if asymmetry matters. A plan should explain whether the existing difference involves volume, position or another feature and how that affects the proposal. Perfect symmetry is not an appropriate assumption. Also distinguish your preference from a generic ideal waist-to-hip shape: the purpose is to understand your own goals, not to meet one universal body template.

Proposed task	Material or approach to discuss	Detail that needs its own explanation
Device-based volume	Gluteal implant	Exact manufacturer, model and intended contour
Volume from your own tissue	Fat grafting	Donor areas and separate grafting safety considerations
Device plus transferred fat	Combined augmentation	What each component adds and its additional risks
Loose skin	Skin-lift or other contouring assessment	Why augmentation alone would or would not address it
Injectable filler offer	Regulatory and safety clarification	It is not equivalent to a surgical implant

The table defines different proposals, not an eligibility checklist. If your goal mainly concerns loose skin, ask why a volume-adding device is being recommended. If the proposal includes additional contouring, record its separate treatment area and endpoint so that you can assess the complete plan.

Request an exact device record

The word silicone does not identify every feature of a gluteal implant. Primary reports describe different devices and materials, and studies from one country or device generation should not be treated as evidence for every current United States product. Ask for the manufacturer, model, material, shape, dimensions, identifying information and patient labeling for the proposed device.

ASPS explains that implant positioning depends on the implant type, desired enlargement, body type and the surgeon’s recommendation. It describes a device made for the buttocks rather than treating any silicone product as interchangeable. ASPS procedure guidance provides that context.

Ask how the device’s shape and dimensions relate to the specific contour goal. A volume number alone does not communicate coverage, region or fit. Request a plain-language account of the placement proposed and the reason for it; this should explain the decision without becoming a surgical instruction or a claim that one placement plane is best for everyone.

Separate the physical device from the surrounding contour plan. If a proposal also changes the waist or adds fat to another region, the overall silhouette cannot be attributed to the implant alone. Ask which part of a selected example comes from each component. Otherwise, an attractive waist-to-hip comparison can suggest that one device produces changes it was never intended to make.

Clearance, approval and a current device are separate questions

FDA describes the 510(k) process as a substantial-equivalence review, distinct from the premarket-approval pathway. Ask which regulatory record applies to the exact proposed product and intended use instead of accepting a blanket phrase such as FDA-approved butt implants. FDA explains the pathways.

For example, FDA’s public record K974482 lists a SILIMED GLUTEAL IMPLANT and a February 24, 1998 substantial-equivalence decision. That historical record is evidence about the identified submission; it is not a recommendation for a particular current model or a guarantee that every gluteal implant is authorized and suitable. The actual FDA record shows its scope.

Keep device identity with your clinical records if surgery proceeds. Ask how the practice provides identification and how future safety notices would be communicated. A generic note that silicone was used is less informative than the model and lot details needed to check a product-specific notice. This is a recordkeeping question, not an instruction to buy or select a device independently.

When reviewing a regulatory record, match the device name and identifier rather than the appearance of a search result. A database entry can refer to a submission made decades earlier, while your proposal may involve a later model or a product used in another market. Ask the clinician to explain the connection with the actual proposed device and provide the relevant labeling. An unmatched record leaves that question unanswered.

Check recall scope without generalizing it

On October 12, 2026, the FDA record for the AART Gluteal Implant recall displayed open, classified status. Recall Z-0945-2026 was initiated by the firm on September 26, 2025, and posted on December 18, 2025. The record identifies models and lots and describes specification and marketing-authorization concerns. The primary FDA recall record contains the exact scope.

A product-specific recall should not be turned into a statement that all butt implants have the same status. Nor does a historical clearance record settle the status of a different product. Ask the treating team to match the actual manufacturer, model and lot against current information. The distinction between initiation, posting and present status matters because those dates describe different events.

If you already have an implant and are unsure which product was used, obtain the operative or device records and discuss the question with the treating clinician. This guide cannot identify your device, determine whether a notice applies or recommend removal. A decision about an existing implant needs the actual record, clinical assessment and current notice instructions, rather than inference from the word silicone.

Keep the date on any recall information you save. A status observed during this article’s research is a dated observation, not a promise that the record will remain unchanged. Model and lot matching should also be recorded separately from the clinical decision. Finding a matching identifier and deciding what care is appropriate are related steps, but the first does not perform the second.

Injectable silicone is not an implant alternative

FDA has not approved injectable silicone or injectable fillers for body contouring or enhancement and warns against injections into the buttocks for that purpose. Potential harms include long-term pain, infection, disfigurement and serious injury or death. FDA explains the distinction and warning.

Do not treat a liquid injection marketed as a nonsurgical implant as the same procedure described here. Ask what substance is being offered and what intended use is actually authorized. A product’s use for another body region does not establish authorization for large-volume buttock enhancement. A reassuring marketing name is not a substitute for an exact product and indication.

Likewise, fat grafting is not the same as injectable silicone. A combined implant-and-fat proposal contains two surgical components with separate considerations. If the treating team suggests fat transfer, ask for a distinct explanation of why it is included and how its safety is addressed. Do not borrow an implant study’s results to claim that every grafting method is safe or vice versa.

Read the implant studies without inventing a winner

A 2023 original retrospective report reviewed 175 consecutive bilateral augmentation cases using solid silicone implants in a specified dual-plane approach, with or without supplemental fat transfer. Infection was reported in 13 cases; seven were superficial and did not require surgical intervention. The abstract also described wound separation, seroma, capsular contracture and migration. The original study defines the observed events.

Thirteen divided by 175 is approximately 7.43 percent. That calculation describes reported infection in that particular case series, not all complications, a national current rate or your individual probability. The seven superficial infections are a subset of the 13, so they must not be added to produce 20 infections. The abstract alone does not establish the complete follow-up duration for the whole cohort.

Another original single-center retrospective report described 30 patients, including 23 women and seven men. Eleven also had fat grafting. Follow-up ranged from two to 52 weeks, with a median of 24 weeks. It reported three implant-related complications: malrotation, infection and extrusion, with the latter two requiring removal. The primary report describes its selected population and observation range.

Evidence question	What to preserve	What not to infer
Who was studied?	Selected cohort, sex distribution and combined procedures	Representation of every candidate
What was counted?	Infection, wound problem, removal or another exact endpoint	One number for all complications
What is the unit?	People, bilateral cases or events	Two implants as two independent patients
How long were they observed?	Actual range, median and missing detail	Maximum follow-up received by everyone
Was there a comparator?	Actual study design and selection	A causal placement-plane winner

In the 30-patient report, the three recorded complications should not be assumed to represent three unique affected people unless that denominator is verified. A one-year maximum follow-up is also not one year of observation for all 30. These distinctions prevent a tidy-looking percentage from overstating what the primary abstract establishes.

A selected cohort is not a personal risk calculator

Both reports studied particular techniques and combined plans. They do not constitute a randomized comparison between placement planes, devices, implants and fat grafting. A reported absence of a particular event in a small cohort cannot prove the event is impossible. Ask the clinician which evidence applies to the same product, technique and goals as your proposal.

Patient-reported satisfaction, observer-rated appearance and adverse events are separate outcomes. A good average appearance score does not mean nobody needed treatment for a complication. Likewise, a case requiring removal does not describe the experience of every participant. Keep the outcome you care about visible rather than combining all favorable and unfavorable observations into one simplified success percentage.

Distinguish enrollment from complete observation as well. A study can include many people while providing uneven follow-up, and an abstract may not expose every missing visit or endpoint. Ask whether a result describes everyone enrolled, only people who returned or a particular subgroup. That difference can affect interpretation even when the arithmetic is correct. If it is not available in the source, the honest answer is that the denominator or observation is unresolved.

When a practice provides its own figures, ask what procedures they cover and how patients who did not return are handled. Ask whether wound issues managed without another operation are included. Clarify the time period and whether the data include combined fat transfer or revisions. A definition and denominator make a number interpretable; reassurance without those details does not.

Discuss implant-specific problems and the contingency plan

ASPS’s implant-specific educational material lists infection, bleeding, wound opening with device exposure, scars, nerve damage, firmness, rupture, migration, fluid collection, sciatic-nerve pressure and anesthesia risks. The society’s implant risk material distinguishes these concerns.

Ask how each relevant issue would be recognized and assessed after your operation. If infection or exposure occurs, what care setting and clinical team would handle it? If the device changes position or becomes uncomfortable, what examination would guide the next decision? The purpose is to understand access to care, not to assume that another procedure will be required or can always solve the concern.

ASPS also lists broader surgical risks including poor healing, persistent pain, sensation changes, blood clots and cardiopulmonary complications. Its general safety guidance covers the wider operation. Discuss your own medical history and the complete proposed scope, including other operations performed together. A device choice does not replace anesthetic or general surgical assessment.

Recovery must match the actual procedure

ASPS describes dressings, possible drains, garments and individualized instructions for follow-up, bathing and return to activity. It separately labels some sitting and exercise advice as fat-grafting guidance. Do not automatically transfer that calendar to an implant-only operation. The source separates the recovery contexts.

Request explicit instructions about sitting, sleeping, walking, driving, work and exercise for your proposed implant placement and any added grafting. Tell the team what your job and home responsibilities involve. A general return-to-work statement is incomplete if it does not distinguish prolonged sitting, lifting or a physical occupation. Ask what observation or assessment supports each progression in activity.

The same ASPS recovery guidance advises immediate medical attention for shortness of breath, chest pain or unusual heartbeats. Do not wait for a routine follow-up or an online reply for those symptoms. Obtain the team’s written instructions for other unexpected changes and clarify who answers outside office hours, especially if surgery and recovery occur far from home.

ASPS notes that the final appearance takes time to develop and that surgical incisions need protection during healing. Its results guidance describes the settling period. Assess contour, comfort, scar and function separately during follow-up. An early photograph should not be presented as proof of a settled or lifelong result.

Bring a complete history and plan for follow-up

ASPS’s general augmentation candidacy guidance emphasizes health, realistic expectations and the specific shape concern. Those factors start the individual assessment. They do not clear a person for a device based only on being lean, wanting projection or finding enough space for a particular volume.

Consultation should include conditions, allergies, previous treatments and operations, medications, supplements and substance use. ASPS explains the history to provide. Disclose prior injections or devices accurately because a new plan needs the actual previous treatment history, not an assumption that the region is untreated.

Preparation may include testing and clinician-directed medication changes, with transport and first-night assistance arranged for outpatient surgery. ASPS preparation guidance supports that planning. Do not independently stop prescribed treatment or follow a regimen copied from a technique article. Establish who will provide follow-up if the original surgical team becomes unavailable.

Compare costs and future-care responsibilities

ASPS lists surgeon, facility, anesthesia, medicines, garments, special recovery pillows and tests among possible costs. A quoted surgical fee should not be treated as the entire episode. Its cost guidance explains the components.

Quote field	Detail to confirm	Why it matters
Device	Model, included implant charge and identifying records	Material alone does not identify the product
Operative scope	Implant-only or combined grafting/contouring	Different treatment areas and risks
Setting	Surgeon, anesthesia and facility amounts	Headline fee may omit major components
Recovery	Visits, supplies and any supported stay	Care needs must be explicit
Unexpected care	Removal/revision responsibility and financial policy	A device warranty is not complete clinical coverage

Compare written proposals after reconciling the device and scope. Ask who pays for different forms of unexpected care, how a manufacturer policy differs from clinical fees and what changes if another operation is needed. The cost planning guide helps organize the full episode without inventing a national total.

The strongest implant decision rests on a traceable device, a defined contour goal and a realistic account of care over time. Preserve those details alongside the consent so that future assessment can rely on the actual operation rather than a generic description of butt enhancement.

If care transfers to another clinician, provide the device identifiers and operative scope with the follow-up history. This makes the handover more informative than a photograph or an approximate implant volume alone.